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Available online 1 June 2016Aim: To determine predisposing factors of idiopathic allograftﬁbrosis among pediatric liver transplant recipients.
Background: Protocol biopsies (PB) from stable liver transplant (LT) recipient children frequently exhibit idio-
pathicﬁbrosis. The relation between allograft inﬂammation, humoral immune response and ﬁbrosis is uncertain.
Also the role of HLA-DRB1 genotype has not been evaluated, though it's associated with ﬁbrosis in autoimmune
hepatitis.
Patients andMethods: This observational study, included 89 stable LT recipient transplanted between 2004–2012
withmean follow-up of 4.3 years, 281 serial PBs (3.1 biopsy/child) and human leukocyte antigen (HLA) antibody
data. PBs were taken 1–2, 2–3, 3–5, 5–7, and 7–10 years post-LT, and evaluated for inﬂammation and ﬁbrosis
using liver allograft ﬁbrosis score (LAFSc). The evolution of ﬁbrosis, inﬂammation and related predisposing fac-
tors were analysed.
Findings: HLA-DRB1*03/04 allele and Class II DSA were signiﬁcantly associated with portal ﬁbrosis (p = 0.03;
p = 0.03, respectively). Portal inﬂammation was predisposed by Class II DSA (p= 0.02) and non-HLA antibody
presence (p= 0.01). Non-portal ﬁbrosis wasn't predisposed by inﬂammation. Lobular inﬂammationwas associ-
ated with non-HLA antibodies.
Interpretation: We conclusively demonstrated that allograft inﬂammation results in ﬁbrosis and is associated
with post-LT Class II DSA and non-HLA antibodies. The HLA-DRB1*03/04 allele caused genetic predisposition
for ﬁbrosis.
Funding: None.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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. This is an open access article under1. Introduction
Given the long-term survival in pediatric liver transplantation (LT),
maintaining stable liver function and preserving allograft histology are
paramount. Protocol biopsies (PBs) from LT recipient children revealed
frequent allograft inﬂammation and ﬁbrosis (Evans et al., 2006;
Scheenstra et al., 2009; Hubscher, 2011; Venturi et al., 2012, 2014;
Gurevich et al., 2015), in stable LT recipients without predisposing fac-
tors (Evans et al., 2006; Venturi et al., 2014; Gurevich et al., 2015;
Miyagawa-Hayashino et al., 2012). The etiopathogenesis of these “idio-
pathic” changes is unknown, while graft age, subclinical rejection and
medication non-compliance have been considered as possible aetiol-
ogies (Hubscher, 2011; Venturi et al., 2014; Miyagawa-Hayashino et
al., 2012). Among these, the donor speciﬁc class II HLA antibodies
have been shown to play an important role in the allograft evolution.
This proposition of antibody mediated subclinical inﬂammation gainsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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shown to correlate with the antibody presence (Miyagawa-Hayashino
et al., 2012; Kozlowski et al., 2011; Salah et al., 2014). While continuity
between uncontrolled inﬂammation and hepatic ﬁbrosis was docu-
mented in hepatitis C and auto-immune hepatitis (AIH), this was not
the case for pediatric LT recipients. To establish a temporal association
between inﬂammation and ﬁbrosis, sequential PBs need to be evaluated
to verify if inﬂammation precedes ﬁbrosis histologically. This has not
been done in the context of pediatric LTwhere all the studies have eval-
uated biopsies cross-sectionally wherein co-existing inﬂammation and
ﬁbrosis could be evaluated but not sequential development (Evans et
al., 2006; Scheenstra et al., 2009). Hence the conﬂictory evidence of in-
ﬂammation not resulting in ﬁbrosis in pediatric LT versus other inﬂam-
matory hepatic diseases. In AIH, the HLA-DRB1*03/04 allele is
considered an independent predictor of portal ﬁbrosis (Montano-Loza
et al., 2006; de Boer et al., 2014; Liberal et al., 2015). As AIH is the pro-
totype of immune dysregulation-mediated hepatic disease, examining
its role in LT recipients is the next logical step: we sought to evaluate
“idiopathic” allograft changes by analysing serial PBs in a complica-
tion-free LT recipient cohort.
1.1. Hypothesis
We hypothesized that ﬁbrosis at time-point t is inﬂuenced by pre-
existing inﬂammation and persistent pre-existing ﬁbrosis at time-
point t− 1. Other factors that could have an impact on these allograft
histological changes are time since LT, presence of HLA and non-HLA an-
tibodies, immunosuppression regime, rejection episodes, HLA-DRB1
status, underlying primary liver disease, donor type (living/deceased),
and host and donor demographic characteristics (Fig. 1).
2. Methods
2.1. Patients
This observational study sought to evaluate successive PBs of includ-
ed childrenwho satisﬁed the criteria of having undergone LT from 2004
to 2012 (i.e., minimum 3-year post-LT follow-up) and having AST, ALT,
GGT levels b 1.5 times upper limit normal at the time of each protocol
biopsy. The exclusion criteria were inadequate PBs. i.e. btwo successiveFig. 1.Hypothesis to test, for development of allograft ﬁbrosis (Our hypothesis for allograft inﬂaPBs, inadequate information regarding HLA antibody status (pre-LT and
simultaneous to last PB), death of LT recipient, re-transplantation, bili-
ary or vascular complications, chronic rejection, previous hepatocyte
treatment or hepatotoxic drug exposure, and combined liver-kidney
transplantation. The screening and inclusion, exclusion steps are as
per Fig. 2.
2.2. Data Collection Methodology
Data was collected as outlined in Fig. 3.
2.3. PB Details
The protocol stipulated performing PBs 1, 2, 3, 5, 7, and 10 years
post-LT. Since LT recipients were all over Europe, not all biopsies follow-
ed the same schedule; we considered PBs taken 1–2 years post-LT as PB
1 and those taken at 2–3, 3–5, 5–7, and 7–10 years as PB 2, PB 3, PB 4,
and PB 5, respectively. Only PBs were evaluated, and no other biopsies
considered.
2.4. Antibody Evaluation
HLA antibody detection was performed using single beads on
Luminex platform, with a mean ﬂuorescence index (MFI) cut-off for
positivity at 1500 (O'Leary et al., 2014; Reed et al., 2013; Musat et al.,
2011). Donor-speciﬁc antibody (DSA) detection was conducted for de-
tectable HLA antibodies.
Non-HLA antibodies (ANA, SMA, and LKM) were evaluated by stan-
dard immune-ﬂuorescence, and considered positive if detected on the
last two PBs with titres N 1:40.
HLA antibodies were tested within 1 month pre-LT and at the last
PB; non-HLA antibodies were tested pre-LT and at the last two PBs.
2.5. Immune Suppression
A steroid-free protocol was used, combining tacrolimus and
basiliximab (Simulect; Novartis Pharma, 1800, Vilvoorde, Belgium).
Two basiliximab doses were administered intravenously at Days 0 and
4 post-LT (10 or 20 mg/dose, for recipient body weight above or
below 35 kg, respectively), followed by tacrolimus alone from Day 1mmation had same variables other than Fibrosis on Protocol biopsy at time point (t− 1)).
Fig. 2. Screening, inclusion and exclusion steps followed in the study.
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target blood trough levels of 8–12 ng/ml during the ﬁrst month post-LT,
5–8 ng/ml for the next 11 months, and 3–5 ng/ml thereafter. Acute cel-
lular rejection was suspected in patients exhibiting increased liver en-
zymes (normal range: alanine aminotransferase [ALT]: 5–40 IU/l and
c-glutamyl transferase [GGT]: 5–40 IU/l), conﬁrmed by histological
signs according to Banff classiﬁcation. Steroids ormycophenolate mofe-
til (MMF) were transiently employed during these episodes. Besides re-
jection, PB observations only induced treatment modiﬁcations in cases
of de-novo autoimmune hepatitis (DNAIH) or DNAIH-like manifesta-
tions. DNAIH was diagnosed from positive autoantibodies, increased
serum gamma-globulin concentrations, and histological features of in-
terface and lobular hepatitis or plasma-cell inﬁltration; steroids, MMF,
or azathioprinewere then administered. Any immunosuppressivemod-
iﬁcationswere documented at each visit, with each regime followed be-
tween two paired PBs categorized as tacrolimus alone or in combination(MMF, azathioprine, or sirolimus). The combined therapy's impact on
allograft histology was compared to that of monotherapy.
2.6. Histological Evaluation
Each PB was evaluated for inﬂammation and ﬁbrosis by three inde-
pendent observers, with a consensus made for categorization differ-
ences. Fibrosis was assessed using the liver allograft ﬁbrosis score
(LAFSc) on Masson's trichrome-stained slides, with scores assigned to
portal, sinusoidal, and central areas, as reported (Venturi et al., 2012).
This is well accepted and a validated ﬁbrosis scoring system in the con-
text of pediatric allograft ﬁbrosis. Histological inﬂammation was
assessed on hematoxylin-eosin-stained slides. Lobular inﬂammation
and portal-tract inﬁltration severity was graded as none, mild, moder-
ate, or severe, as detailed in Table 1.
2.7. Data Evaluation and Statistics
Since portal area (LAFSc-P), sinusoidal (LAFSc-S), and central
(LAFSc-C) ﬁbrosis are ordinal variables, their respective evolutions
were analysed using cumulative logisticmixed-effectmodels. The ﬁbro-
sis severity in a given PB at time-point twasmodelled using ﬁxed effect
variables, including predictors of primary interest (inﬂammation and ﬁ-
brosis at previous PB [time-point t− 1]; Class I and II HLA antibodies;
ANA, SMA, and LKM status; additional immunosuppression exposure;
HLA-DRB1), predictors of the model's face validity (time since LT and
living/deceased donor status), and others additional predictors (donor
and recipient ages, recipient gender, underlying primary liver disease,
and total rejection number). A random patient effect was introduced
into eachmodel for inter-patient differences. Portal tract and lobular in-
ﬂammation evolutionwas analysed using cumulative logistic mixed-ef-
fect models with the same predictors, except previous PB ﬁbrosis.
Given the number of potential predictors and because our main
focus was on clinical and biological variables, a predictor selection pro-
cedure was conducted as previously described (Vittinghoff et al., 2012).
All primary interest predictors and those required for establishing the
model's face validity were systematically included, regardless of their
statistical signiﬁcance. A backward elimination was then applied on ad-
ditional predictors in order to produce more parsimonious models by
removing non-signiﬁcant (p N 0.10) variables.
Mixed-effectmodelswere built using the clmm2 function fromordi-
nal R package, and the maximum likelihood estimations of parameters
were computed via adaptive Gauss-Hermite quadrature approximation,
as previously recommended (Christensen, 2015). Statistical signiﬁcance
of multi-level variables was computed using a likelihood ratio test.
Predisposing factors for post-LT Class II HLA DSA were assessed
using a logistic-regression model, built using the glm R function.
In a spirit of “Reproducible Research”, all statistical analyses are re-
ported in R Markdown ﬁle which are provided in Supplementary ﬁles
3 (LAFSc-P), 4 (LAFSc-C), 5 LAFSc-S), 6 (Portal Inﬂammation), 7 (Lobular
Inﬂammation), and 8 (predisposing factor to develop Class II HLA-DSA).
3. Funding
No external funding or non-funding support was taken in this study.
4. Ethical clearance
Appropriate ethical clearance was obtained from our institutional
board.
5. Results
We included 89 children as described in Fig. 2, with 281 PBs, com-
prising 189 pairs of successive PBs (average of 3.15 biopsies per
Fig. 3.Data collection time points and schematic, representative of a patient followed up for N10 years. LT: Liver transplantation, PB: Protocol biopsy, HLA Ab: HLA antibody, Non-HLA Ab:
Non-HLA antibodies (ANA or SMA or LKM), IS: Immune suppression.
349S. Varma et al. / EBioMedicine 9 (2016) 346–355patient). Characterization features are summarized in Table 2 and de-
tails provided in Supplementary Tables 1 and 2.
5.1. Allograft Inﬂammation and Fibrosis Evolution Patterns in Portal, Sinu-
soidal, and Central Areas Were Patient-speciﬁc
Graphical exploration (Fig. 4) of longitudinal allograft inﬂammation
and ﬁbrosis demonstrates our data sets' complex nature. The mean
LAFSc total score at baseline (that is PB1) was 3.32 with 54.6% of chil-
dren having low ﬁbrosis (LAFSc total ≤ 3), 42.0% havingmoderate ﬁbro-
sis (LAFSc total between 4 and 5), and only 3.4% having high ﬁbrosis
(LAFSc total ≥ 6). Subsequent PB showed that no generalizable patterns
can be identiﬁed, with progression and regression patterns tending to
be patient-speciﬁc.
The complex graphical representation rendered it difﬁcult to deci-
pherwhichhistological characteristics present smooth or discontinuous
dynamic evolution. Although average ﬁbrosis stabilised over time
(black stars in Fig. 4), this may have been biased by the numerousmiss-
ing data for the last biopsies. Further statistical analysis using cumula-
tive logistic mixed-effect models were thus undertaken to (i) conﬁrm
this apparent average ﬁbrosis stability, (ii) detect any correlation be-
tween successive PBs from the samepatient, and (iii) identify signiﬁcant
predictors of ﬁbrosis and inﬂammation severity.
5.2. Portal Fibrosis Correlatedwith Preceding Portal Inﬂammation, Presence
of Class II DSA, and Recipient HLA-DRB1 Status
Portal ﬁbrosis at any time-point t signiﬁcantly correlatedwith portal
inﬂammation severity at t − 1. OR strength and signiﬁcance were
higher for severe inﬂammation (OR = 148) or moderate (OR = 10.3)Table 1
Histological inﬂammation scoring system.
Mild
Portal tract
inﬂammation
Discreet inﬁltration of lympho-plasmocytes or lymphoid
aggregates
Lobular inﬂammation Discreet inﬁltration of lympho-plasmocytes or lymphoid
aggregatesthanmild (OR=3.64) (Table 3), implying that preceding portal inﬂam-
mation and also its severity signiﬁcantly impact portalﬁbrosis in a given
biopsy. Class II DSA antibody status (OR = 5.84, p = 0.02) and HLA-
DRB1*03/04 genotype (OR = 2.28, p = 0.03) signiﬁcantly correlated
with higher ﬁbrosis.5.3. Sinusoidal Fibrosis Did Not Correlated with Preceding Inﬂammation
Sinusoidal, unlike portal, ﬁbrosis at a given time-point t did not cor-
relate with inﬂammation at previous time-point t− 1 (Table 4). The as-
sociation with recipient HLA DRB1 status was also weaker (OR = 1.93,
p= 0.08) in the sinusoidal area than in the portal area. Regarding sinu-
soidal ﬁbrosis (Table 4), underlying primary liver disease and total
number of rejections were removed from the model as both variables
were not associated (p-value N 0.10) with the outcome. On the other
hand, recipient age (p-value = 0.08) and gender (p-value = 0.07)
were not eliminated, as a liberal criterion is usually recommended dur-
ing the backward elimination process in order to rule out confounding
factors more effectively.5.4. Central Fibrosis Correlatedwith Pre-existing Fibrosis and Deceased-do-
nor Transplant
Central ﬁbrosis at any time-point t signiﬁcantly (pb 0.01) correlated
with central ﬁbrosis severity at t − 1 (Table 5). ORs correlated with
LAFSc-C severity, conﬁrming thatﬁbrosis persists over time,with higher
ﬁbrosis in a previous PB indicating increased ﬁbrosis persistence risk in
the current PB. Among other predictors, the strongest association was
found with deceased donors (OR = 2.89, p = 0.01).Moderate Severe
Lympho-plasmocytic inﬁltrates but no interface
hepatitis
Presence of interface
hepatitis
Lympho-plasmocytic inﬁltrates but no lobular
necrosis
Presence of lobular necrosis
Table 2
Demographic and clinical characteristics of patients at baseline.
Characteristic. Clinical series (n = 89).
Underlying primary liver disease (no./%). .
Biliary atresia 52/58.4%
Alagille 8/9.0%
Familial cholestasis 5/5.6%
Ductal plate abnormality (CHF) 3/3.4%
Metabolic liver disease 9/10.1%
Malignant disease 8/9.0%
Criggler Najjar 1/1.1%
Indeterminate cirrhosis 3/3.4%
Number of acute rejection episodes (no./%)
None 22/24.7%
1 30/33.7%
2 24/27.0%
3 11/12.4%
4 2/2.2%
Age at LT (yrs.) (mean/SD)
Recipient 3.2/4.1
Donor 30.9/10.02
Recipient gender distribution
Males (no./%) 37/41.6%
Donor type
Living (no./%) 74/83.1%
Duration of follow up since LT (yrs)
Mean/SD 4.3/2.5
Recipient HLA DRB1*03/04 status
Positive/Negative 39/50
Pre-LT HLA antibody status (no./%)
Class I HLA antibodies
Neg 75/84.3%
Non DSA 9/10.1%
DSA 5/5.6%
Class II HLA antibodies
Neg 83/93.3%
Non DSA 4/4.5%
DSA 2/2.2%
Post-LT HLA antibody status (no./%)
Class I HLA antibodies.
Neg 63/70.8%
Non DSA 18/20.2%
DSA. 8/9.0%
Class II HLA antibodies
Neg 62/69.7%
Non DSA 12/13.5%
DSA 15/16.8%
Number of patients with successive PBs (no./%) .
2 successive PBs 29/32.6%
3 successive PBs 29/32.6%
4 successive PBs 22/24.7%
5 successive PBs 9/10.1%
LT: liver transplant; PB: protocol biopsy; PB 1: protocol biopsy taken between 1–2 years
post LT; PB 2: protocol biopsy taken between 2–3 years post LT; PB 3: protocol biopsy
taken between 3–5 years post LT; PB 4: protocol biopsy taken between 5–7 years post
LT; PB 5: protocol biopsy taken between 7–10 years post LT; SD: standard deviation;
HLA: human leukocyte antigen; DSA: donor-speciﬁc (HLA) antibodies.
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DSA, and Non-HLA Antibodies
Portal inﬂammation at any time-point t signiﬁcantly correlated
(p b 0.01) with portal inﬂammation severity at t − 1 (Table 6). OR
strength and signiﬁcance correlated with severity, suggesting a strong
persistence of severe inﬂammation. Other signiﬁcant predictors of por-
tal inﬂammation included Class II DSA (OR = 4.77, p = 0.02) and non-
HLA antibodies (OR = 2.31, p = 0.01).5.6. Lobular Inﬂammation Correlated with Pre-existing Lobular Inﬂamma-
tion and Non-HLA Antibodies
A strong persistence of lobular inﬂammationwas detected via highly
signiﬁcant ORs positively correlated with previous PB inﬂammationseverity. Lobular inﬂammation severity was signiﬁcantly impacted by
non-HLA antibodies (OR = 2.28, p-value = 0.05).
5.7. Post-LT Class II DSAWere Determined By Donor and Recipient Age and
Impacted Allograft Evolution
Post-LT Class II DSAswere observed in 15/89 (16.8%) children (Table
2). Of these, 13 developed them “de-novo”, i.e., no pre-LT expression
(Fig. 5). The strongest predictor of post-LT Class II DSAs was donor age
(Table 8). For each 1-year increase in donor age, the odds of developing
post-LT Class II DSAs decreased by over 10% (OR = 0.89, p b 0.01). On
other hand, Post-LT DSAs was positively and signiﬁcantly associated
with recipient age (OR = 1.21, p = 0.03). Both results indicate that
older donor age decreases the risk of developing class II DSA while
older recipient age increases this risk.
While time since transplantationwas not signiﬁcant (p=0.37), lon-
ger time (N5 years) correlated with higher ORs, post-LT Class II DSA
tending to increase over time. Antibody presence signiﬁcantly correlat-
ed with portal inﬂammation (OR = 4.77, p = 0.02) and ﬁbrosis (OR =
5.84, p = 0.02) evolution (Tables 3 and 6).
5.8. HLA-DRB1*03/04 Allele in Recipients Was Associated with Allograft
Portal and Sinusoidal Fibrosis
HLA-DRB1*03/04 allele in recipients was positively correlated
(OR N 1) with allograft ﬁbrosis in both portal and sinusoidal areas. The
association was stronger in the portal (OR = 2.28, p = 0.03) than in
the sinusoidal (OR = 1.93, p = 0.08) part, where the association was
found not to be signiﬁcant.
No signiﬁcant difference (p = 0.45) was found between the preva-
lence of HLA-DRB1*03/04 allele between patients with biliary atresia
(25/52, 48.1%) versus patients with others indications for LT (14/37,
37.8%).
5.9. Age, Gender, Underlying Primary Liver Disease, and Number of Rejec-
tions Were Not Associated with Fibrosis and Inﬂammation
Regarding portal and central ﬁbrosis and portal and lobular inﬂam-
mation (Tables 3, 5, 6, 7), non-signiﬁcant (p-value N 0.10) associations
were found for donor and recipient ages, recipient gender, underlying
primary liver disease, and total number of rejections. Considering that
these non-signiﬁcant variables are neither of primary interest nor re-
quired to guarantee the face validity of the model, they were removed
during backward elimination in order to produce more parsimonious
models. Regarding sinusoidal ﬁbrosis (Table 4), underlying primary
liver disease and total number of rejections were removed from the
model as both variables were not associated (p-value N 0.10) with the
outcome. On the other hand, recipient age (p-value= 0.08) and gender
(p-value = 0.07) were not eliminated, as a liberal criterion is usually
recommended during the backward elimination process in order to
rule out confounding factors more effectively.
6. Discussion
Allograft histological inﬂammation was shown not to be innocuous,
eventually resulting in ﬁbrosis, and associated with post-LT Class II DSA
and persistent non-HLA antibodies. HLA-DRB1*03/04 allele in LT recip-
ients was an independent predisposing factor for developing ﬁbrosis,
without inﬂuencing inﬂammation.
This is a unique study, involving an uncomplicated patient cohort,
which focused on serial PBs to delineate idiopathic ﬁbrosis and inﬂam-
mation in allografts and explored their predictors, using paired PBs,
studying the impact of pre-existing ﬁbrosis and inﬂammation on cur-
rent ﬁbrosis and inﬂammation, assessing correlations with various
HLA and non-HLA antibodies, and applying statistical models enabling
the representation of each patient's evolution pattern. We also focused
Fig. 4. Individual (gray circles) and averaged (black stars) evolutions of ﬁbrosis across serial protocol biopsies are shown. Longitudinal evolution of each patient is plotted independently
using the gray circles at different time-points and connected via solid lines. Longitudinal evolution of ﬁbrosis (a,b,c,d) and inﬂammation (e,f) across the 5 protocol biopsies. Each graphic
reports the longitudinal evolution of one speciﬁc histological feature (a: Portal Fibrosis, b: Sinusoidal Fibrosis, c: Central Fibrosis, d Total (i.e., Portal + Sinusoidal + Central) Fibrosis, e:
Portal inﬂammation, f: lobular inﬂammation). Within each graphic, individual evolution of each patient is reported with connected gray circles while averaged evolution is reported
with black stars. Based on these graphics, no generalizable patterns were identiﬁed for each histological feature.
351S. Varma et al. / EBioMedicine 9 (2016) 346–355on different hepatic parenchyma zones using LAFSc (Venturi et al.,
2012). This zone-speciﬁc analysis enabled us to decipher cause-speciﬁc
inﬂammation and ﬁbrosis patterns, resulting in a scheme for PB inter-
pretation (Fig. 6).
In previous studies evaluating PBs, ﬁbrosis prevalence was N70% at
5 years post-LT, with none exhibiting normal histology after 10 years
(Evans et al., 2006; Scheenstra et al., 2009; Venturi et al., 2014). In a clin-
ical series with similar mean ﬁbrosis evolution as in our cohort (LAFSc
total = l2.91 vs 3.32 at baseline, and 3.31 vs 3.76 at 3 years post LT),
Venturi et al. demonstrated that ﬁbrosis in pediatric LT recipients is
not a “one-way street” and regression frequently occurs (Venturi etal., 2014; Chevallier et al., 1994). Computing mean ﬁbrosis would thus
not provide information about a patient-speciﬁc evolution, as in our
study (Fig. 4). We thus implemented cumulative logistic mixed-effect
models for statistical analysis, enabling representation of each patient's
course.
Portal tracts are immunologically-active zones with high hepatic
stellate cell (HSC) levels (Maia et al., 2010). HSCs can be either
ﬁbrogenic when activated by persistent inﬂammation or ﬁbrinolytic in
quiescent state (Kisseleva et al., 2012; Troeger et al., 2012; Mallat and
Lotersztajn, 2013). Portal inﬂammation, which would thus be pro-
ﬁbrogenic, was shown to persist across serial PBs (Table 6), correlating
Table 3
Multivariate analysis using cumulative logistic mixed effect model to determine correla-
tion between current portal ﬁbrosis and various variables listed in the table.
Variable Odds-ratio (95% CI)a p-valuea
Previous portal ﬁbrosis (LAFSc-P) (t− 1) 0.39
0 1.0 –
1 2.20 (0.51–9.48) 0.29
2 3.45 (0.76–15.6) 0.11
3 4.17 (0.73–23.8) 0.11
Previous portal inﬂammation (t− 1) b0.01
none 1.0 –
mild 3.64 (1.44–9.18) b0.01
moderate 10.3 (3.41–30.9) b0.01
severe 148 (11.8–1870) b0.01
Class I HLA 0.64
Neg 1.0 –
Not DSA 0.67 (0.25–1.76) 0.41
DSA 1.39 (0.23–8.39) 0.72
Class II HLA b0.01
Neg 1.0 –
Not DSA 3.56 (0.92–13.8) 0.07
DSA 5.84 (1.36–25.0) 0.02
Other antib (ANA or SMA or LKM)
Neg 1.0 –
Pos 0.60 (0.30–1.18) 0.14
Additional immunosuppression exposure
No 1.0 –
Yes 0.86 (0.34–2.21) 0.76
Recipient HLA DRB1*03/04
Neg 1.0 –
Pos 2.28 (1.06–4.89) 0.03
Time since transplantation 0.40
2–3 yr 1.0 –
3–5 yr 0.82 (0.41–1.64) 0.58
5–7 yr 0.54 (0.21–1.37) 0.19
N 7 yr 0.36 (0.08–1.58) 0.17
Donor status
Living 1.0 –
Deceased 1.90 (0.76–4.80) 0.17
CI: conﬁdence interval; LAFSc: liver allograft ﬁbrosis scoring; HLA: human leukocyte anti-
gen; DSA: donor-speciﬁc (HLA) antibodies.
a Odds-ratio, 95% conﬁdence intervals (CI), and p-value were obtained from a cumu-
lative logistic mixed effect model. This model included all predictors of primary interest
and all predictors of the model's face validity. This model resulted from a backward elim-
ination process which eliminated non-signiﬁcant (p-value N 0.10) additional predictors
including donor and recipient ages, recipient gender, underlying primary liver disease,
and total number of rejections.
Table 4
Multivariate analysis using cumulative logistic mixed effect model to determine correla-
tion between current sinusoidal ﬁbrosis and various variables listed in the table.
Variable Odds-ratio (95% CI)a p-valuea
Previous sinusoidal ﬁbrosis (LAFSc-S) (t− 1) 0.26
0 1.0 –
1 1.36 (0.56–3.27) 0.50
2 3.55 (0.77–16.5) 0.10
Previous lobular inﬂammation (t− 1) 0.59
None 1.0 –
Mild 1.72 (0.78–3.82) 0.18
moderate 1.18 (0.27–5.04) 0.83
severe 1.69 (0.02–166.2) 0.82
Class I HLA 0.58
Neg 1.0 –
Not DSA 0.79 (0.26–2.37) 0.67
DSA 0.41 (0.07–2.40) 0.32
Class II HLA 0.78
Neg 1.0 –
Not DSA 1.45 (0.39–5.37) 0.58
DSA 0.79 (0.19–3.23) 0.74
Other antib (ANA or SMA or LKM)
Neg 1.0 –
Pos 0.60 (0.28–1.30) 0.20
Additional immunosuppression exposure
No 1.0 –
Yes 1.47 (0.60–3.59) 0.40
Recipient HLA DRB1*03/04
Neg 1.0 –
Pos 1.93 (0.93–3.98) 0.08
Time since transplantation 0.26
2–3 yr 1.0 –
3–5 yr 0.58 (0.26–1.27) 0.17
5–7 yr 1.45 (0.53–3.93) 0.47
N 7 yr 0.47 (0.11–2.07) 0.32
Donor status
Living 1.0 –
Deceased 1.94 (0.76–4.94) 0.17
Recipient age (yr) 0.92 (0.83–1.01) 0.08
Recipient gender
Male 1.0 –
Female 2.02 (0.96–4.29) 0.07
CI: conﬁdence interval; LAFSc: liver allograft ﬁbrosis scoring; HLA: human leukocyte anti-
gen; DSA: donor-speciﬁc (HLA) antibodies.
a Odds-ratio, 95% conﬁdence intervals (CI), and p-value were obtained from a cumu-
lative logistic mixed effect model. This model included all predictors of primary interest
and all predictors of the model's face validity. This model resulted from a backward elim-
ination process which eliminated non-signiﬁcant (p-value N 0.10) additional predictors
including recipient ages, underlying primary liver disease, and total number of rejections.
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tor of portal ﬁbrosis in the next PB (Table 3). Despite the well-docu-
mented link between inﬂammation and ﬁbrosis in hepatitis C, such
link remained inconclusive in pediatric LT. A Birmingham study on
PBs 1, 5, and 10 years post-LT demonstrated greater ﬁbrosis in biopsies
with co-existing chronic hepatitis, inﬂammatory activity being not pre-
dictive of consequentﬁbrosis (Evans et al., 2006). The authors evaluated
ﬁbrosis and inﬂammation cross-sectionally at three time-points over
10 years.
While other studies had similarﬁndings (Herzog et al., 2008), our re-
sults contradict these, as preceding inﬂammation and its intensity cor-
related with subsequent ﬁbrosis. To explain this discrepancy, we
correlated ﬁbrosis at time-point t to inﬂammation at t− 2 (Supplemen-
tary Table 9) tomimic the PB intervals of the Birmingham study, reveal-
ing no correlation. Hence, the discrepancieswere likely produced by our
shorter PB intervals rather than between-cohort differences. Theseﬁnd-
ings suggest our PB schedule to be appropriate for further prospective
studies on allografts.
Portal inﬂammation was signiﬁcantly associated with Class II DSA
and non-HLA antibodies, as expected, since DSAs have been implicated
in allograft inﬂammation, ﬁbrosis, and biliary and vascular complica-
tions (O'Leary et al., 2014). Although MHC Class II (major histocompat-
ibility complex) is expressed by specialised antigen-presenting cells and
not hepatocytes, hepatocytes facing persistent insult were recentlyshown to exhibit these antigens (Yamagiwa et al., 2014), especially in
the periportal regions. This could explain the association betweenportal
inﬂammation and Class II DSAs. A study collecting serial HLA antibody
and inﬂammation data at each PB is required to investigate whether
Class II DSA precedes or follows inﬂammation.
Most of our DSAs were “de-novo”, and their development was pre-
dicted by donor and recipient ages. Other studies reported younger
age at LT and medication non-compliance to be predisposing factors,
which was not conﬁrmed in our cohort (Del et al., 2014). Only three
children developed both Class II DSA and non-HLA antibodies, hinting
at different etiopathogeneses. In line with previous results (Venturi et
al., 2014), we found non-HLA antibodies to be associated with portal
and lobular inﬂammation. Non-HLA antibodies were detected in 40–
75%of post-LT cases (Chen et al., 2013), associatedwith acute rejections,
chronic rejections, and DNAIH. Since transient positivity can occur with
rejection episodes, we considered non-HLA antibodies as positivewhen
detected at the last two PBs.
HLA-DRB1*03/04 allele in LT recipients was an independent risk fac-
tor for portalﬁbrosis, with no signiﬁcant associationwith inﬂammation.
This corresponds to the AIH scenario Montano-Loza et al., 2006; Liberal
et al., 2015. These alleles are believed to result in faulty antigen process-
ing, with antigenicmimicry resulting in hepatic injury. Given that, with-
in 4 weeks, the recipient's Kuffer cells were shown to completely
Table 5
Multivariate analysis using cumulative logistic mixed effect model to determine correla-
tion between central ﬁbrosis and various variables listed in the table.a*
Variable Odds-ratio (95% CI)a p-valuea
Previous central ﬁbrosis (LAFSc-C) (t− 1) b0.01
0 1.0 –
1 4.51 (1.61–12.6) b0.01
2 9.41 (2.71–32.7) b0.01
3 92.5 (3.50–2449) b0.01
Previous lobular inﬂammation (t− 1) 0.17
none 1.0 –
mild 1.55 (0.72–3.31) 0.26
moderate 0.44 (0.12–1.58) 0.21
severe 1.36 (0.03–72.1) 0.88
Class I HLA 0.43
Neg 1.0 –
Not DSA 1.39 (0.52–3.72) 0.51
DSA 0.42 (0.08–2.14) 0.30
Class II HLA 0.34
Neg 1.0 –
Not DSA 1.75 (0.51–6.01) 0.37
DSA 2.42 (0.61–9.60) 0.21
Other antib (ANA or SMA or LKM)
Neg 1.0 –
Pos 0.55 (0.27–1.11) 0.09
Additional immunosuppression exposure
No 1.0 –
Yes 2.21 (0.96–5.09) 0.06
Recipient HLA DRB1*03/04
Neg 1.0 –
Pos 1.42 (0.73–2.76) 0.30
Time since transplantation 0.66
2–3 yr 1.0 –
3–5 yr 1.14 (0.54–2.39) 0.73
5–7 yr 1.35 (0.54–3.36) 0.51
N 7 yr 0.52 (0.13–2.18) 0.37
Donor status
Living 1.0 –
Deceased 2.89 (1.25–6.67) 0.01
CI: conﬁdence interval; LAFSc: liver allograft ﬁbrosis scoring; HLA: human leukocyte anti-
gen; DSA: donor-speciﬁc (HLA) antibodies.
a Odds-ratio, 95% conﬁdence intervals (CI), and p-value were obtained from a cumu-
lative logistic mixed effect model. This model included all predictors of primary interest
and all predictors of the model's face validity. This model resulted from a backward elim-
ination process which eliminated non-signiﬁcant (p-value N 0.10) additional predictors
including donor and recipient ages, recipient gender, underlying primary liver disease,
and total number of rejections.
Table 6
Multivariate analysis using cumulative logistic mixed effect model to determine correla-
tion between portal inﬂammation and various variables listed in the table.a*
Variable Odds-ratio (95% CI)a p-valuea
Previous portal inﬂammation (t− 1) b0.01
none 1.0 –
mild 4.91 (2.00–12.1) b0.01
moderate 29.6 (10.2–85.4) b0.01
severe 78.9 (13.8–451) b0.01
Class I HLA 0.54
Neg 1.0 –
Not DSA 0.73 (0.27–1.96) 0.53
DSA 0.48 (0.11–2.15) 0.34
Class II HLA 0.02
Neg 1.0 –
Not DSA 2.98 (0.90–9.29) 0.07
DSA 4.77 (1.22–18.6) 0.02
Other antib (ANA or SMA or LKM)
Neg 1.0 –
Pos 2.31 (1.18–4.49) 0.01
Additional immunosuppression exposure
No 1.0 –
Yes 0.71 (0.29–1.73) 0.45
Recipient HLA DRB1*03/04
Neg 1.0 –
Pos 1.42 (0.76–2.67) 0.28
Time since transplantation 0.01
2–3 yr 1.0 –
3–5 yr 0.76 (0.39–1.51) 0.43
5–7 yr 1.10 (0.47–2.56) 0.82
N 7 yr 0.09 (0.02–0.45) b0.01
Donor status
Living 1.0 –
Deceased 1.91 (0.91–4.02) 0.09
CI: conﬁdence interval; LAFSc: liver allograft ﬁbrosis scoring; HLA: human leukocyte anti-
gen; DSA: donor-speciﬁc (HLA) antibodies.
a Odds-ratio, 95% conﬁdence intervals (CI), and P-value were obtained from a cumula-
tive logistic mixed effectmodel. This model included all predictors of primary interest and
all predictors of themodel's face validity. Thismodel resulted fromabackward elimination
process which eliminated non-signiﬁcant (P-value N0.10) additional predictors including
donor and recipient ages, recipient gender, underlying primary liver disease, and total
number of rejections.
Fig. 5. Demonstrates the fate of pre-LT class II DSA and the development of “de-novo”
antibodies post LT in all cases except two. Evolution of Class II HLA DSA status recorded
1 month pre-LT and at the last PB. Individual evolution of each patient is reported with
connected gray circles while averaged evolution is reported with black stars.
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presenting cell defects would be evident in the new graft, explaining
our ﬁndings.
Among other factors that can potentially cause histological idiopath-
ic changes in the allograft, immunosuppression medication compliance
and adequacy is important. The methods to verify compliance should
include evaluation of sudden changes in blood levels of the drug, unex-
plained late rejection episodes and patient questionnaires. However as
this study included only patients who were stable and under close fol-
low up, this aspect could have been minimized. Another facet that
needs to be considered before generalization of these results is that
this study included a much selected cohort of stable pediatric LT recipi-
ents; hence universal application of these ﬁndings would be a big
extrapolation.
Topographic ﬁbrosis distribution was a unique aspect of this study.
This enabled us to identify a stronger persistence versus a discontinuous
evolution in central and sinusoidal area, respectively. We found de-
ceased donor to be the only predisposing factor for central ﬁbrosis.
While vascular and biliary complications, chronic rejection have been
reported in earlier studies (Venturi et al., 2014), these were exclusion
criteria in the current study as they are known ﬁbrogenic complications.
Inﬂammation in non-portal, unlike portal, areas was neither predictive
of ﬁbrosis nor associated with Class II DSA, but rather associated withnon-HLA antibodies. We speculate that inﬂammation-driven ﬁbrosis,
when mediated by DSA, is limited to portal areas.
These ﬁndings pave the way for further intervention studies where-
in additional drugs could beused todiminish the inﬂammation and con-
sequent ﬁbrosis. The anti-inﬂammation strategies could be customised
depending on the probable mechanisms, which could be Azathioprine
Table 7
Multivariate analysis using cumulative logistic mixed effect model to determine correla-
tion between lobular inﬂammation and various variables listed in the table.
Variable Odds-ratio (95% CI)a p-valuea
Previous lobular inﬂammation (t− 1) b0.01
none 1.0 –
mild 3.19 (1.49–6.83) b0.01
moderate-severe 27.4 (6.46–116.1) b0.01
Class I HLA 0.11
Neg 1.0 –
Not DSA 0.37 (0.13–1.02) 0.05
DSA 1.84 (0.34–9.96) 0.48
Class II HLA 0.31
Neg 1.0 –
Not DSA 2.18 (0.61–7.78) 0.23
DSA 2.14 (0.49–9.30) 0.31
Other antib (ANA or SMA or LKM)
Neg 1.0 –
Pos 2.28 (1.01–5.16) 0.05
Additional immunosuppression exposure
No 1.0 –
Yes 1.27 (0.54–2.97) 0.58
Recipient HLA DRB1*03/04
Neg 1.0 –
Pos 1.21 (0.62–2.39) 0.57
Time since transplantation 0.30
2–3 yr 1.0 –
3–5 yr 0.84 (0.40–1.79) 0.66
5–7 yr 1.33 (0.52–3.36) 0.55
N 7 yr 0.30 (0.07–1.32) 0.11
Donor status
Living 1.0 –
Deceased 0.96 (0.43–2.15) 0.92
CI: conﬁdence interval; LAFSc: liver allograft ﬁbrosis scoring; HLA: human leukocyte anti-
gen; DSA: donor-speciﬁc (HLA) antibodies.
a Odds-ratio, 95% conﬁdence intervals (CI), and p-value were obtained from a cumu-
lative logistic mixed effect model. This model included all predictors of primary interest
and all predictors of the model's face validity. This model resulted from a backward elim-
ination process which eliminated non-signiﬁcant (p-value N 0.10) additional predictors
including donor and recipient ages, recipient gender, underlying primary liver disease,
and total number of rejections.
Fig. 6.Mechanism of “idiopathic” allograft histological changes.
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sions when there is suspicion of decreased regulation. Also recipients
with HLA DRB1*03/04 could be regarded as high risk of ﬁbrosis and be
monitored more closely.
7. Conclusion
Genetic predisposition, allo-antibodies and allograft inﬂammation
contribute to long term graft ﬁbrosis. The portal ﬁbrosis is strongly asso-
ciated with presence and severity of the preceding inﬂammation, while
this is not seen in the non-portal areas. These factors should thus beTable 8
Predisposing factors to development of class II DSA.a
Variable Odds-ratio (95% CI)a p-valuea
Gamma globulin level 0.99 (0.84–1.16) 0.87
Total number of rejections 0.62 (0.28–1.34) 0.22
Time since LT (years) 0.37
1–3 1.0 –
3–5 2.99 (0.44–20.4) 0.26
5–7 4.62 (0.62–34.3) 0.13
N 7 4.38 (0.51–37.9) 0.18
Recipient age (years) 1.21 (1.02–1.44) 0.03
Donor age (years) 0.89 (0.83–0.96) b0.01
CI: conﬁdence interval; LT: liver transplant; ACR: acute cellular rejection;HLA: human leu-
kocyte antigen; DSA: donor-speciﬁc (HLA) antibodies.
a Odds-ratio, 95% conﬁdence intervals (CI), and p-value were obtained from a logistic
regressionmodel. This model included all predictors of primary interest and all predictors
of themodel's face validity and resulted from a (backward) elimination of one non-signif-
icant additional predictor (Recipient gender, p N 0.10).monitored post-LT and could be used in customization of immune
suppression.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.05.040.
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